Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors
This study is a single arm, pilot study of Sunitinib in patient with RET fusion positive, FGFR2 fusion/FGFR mutation Refractory solid tumor and/or specific sensitivity to Sunitinib by Avatar scan that has progressed following standard therapy or that has not responded to standard therapy or for which there is no standard therapy.

To investigate the efficacy and safety of Sunitinib in patient with Refractory solid tumor.
Refractory Solid Tumors
DRUG: Sunitinib
progression-free survival, 24 months
overall response rate, 24 months|Time to progression, 24 months|overall survival, 24 months|Number of subjects with adverse events as a measure of safety, 24 months
This study is a single arm, pilot study of Sunitinib in patient with RET fusion positive, FGFR2 fusion/FGFR mutation Refractory solid tumor and/or specific sensitivity to Sunitinib by Avatar scan that has progressed following standard therapy or that has not responded to standard therapy or for which there is no standard therapy.

To investigate the efficacy and safety of Sunitinib in patient with Refractory solid tumor.